Kirha Logo

BRCA2-mutant mCRPC — which PARP inhibitors share the same drug class, which are EMA-authorised, what do PROfound and TALAPRO-2 show, and what does the FDA require as companion diagnostic?

I will identify the drug class for Olaparib to confirm the PARP inhibitor classification shared by these agents. Checking EMA authorization status for Olaparib. Checking EMA authorization status for Talazoparib. Checking EMA authorization status for Rucaparib. Checking EMA authorization status for Niraparib. Searching for the PROfound trial to retrieve its NCT ID and summary. Searching for the TALAPRO-2 trial to retrieve its NCT ID and summary. Retrieving detailed results and outcomes for the PROfound trial (Olaparib in mCRPC). Retrieving detailed results and outcomes for the TALAPRO-2 trial (Talazoparib + Enzalutamide in mCRPC). Searching FDA labels for Olaparib (Lynparza) to identify the required companion diagnostic for BRCA2-mutant mCRPC. Searching FDA labels for Talazoparib (Talzenna) to identify the required companion diagnostic for mCRPC.

Below is a structured overview for BRCA2‑mutant metastatic castration‑resistant prostate cancer (mCRPC) covering drug class, EMA status, pivotal trials (PROfound, TALAPRO‑2), and FDA companion diagnostics.

1️⃣ Drug class: Which PARP inhibitors share the same class?

All of the following belong to the same pharmacologic class:

Poly (ADP‑ribose) polymerase (PARP) inhibitors

Key PARP inhibitors relevant to prostate cancer

Drug (Brand)
INN
Class
Olaparib (Lynparza)
olaparib
PARP inhibitor
Talazoparib (Talzenna)
talazoparib
PARP inhibitor
Niraparib (Zejula / in Akeega combo)
niraparib
PARP inhibitor
Rucaparib (Rubraca)
rucaparib
PARP inhibitor

Mechanism: Inhibit PARP‑mediated DNA repair → synthetic lethality in tumors with homologous recombination repair (HRR) defects, especially BRCA1/2 mutations.

For BRCA2-mutant mCRPC, the most clinically established agents are:

  • Olaparib
  • Talazoparib (with enzalutamide)

2️⃣ Which are EMA‑authorised for prostate cancer?

✅ Olaparib (Lynparza)

  • EMA status: Authorised
  • Indication (prostate cancer):
    • Monotherapy for BRCA1/2‑mutated mCRPC after progression on a new hormonal agent
    • In combination with abiraterone + prednisone/prednisolone for mCRPC

✅ Talazoparib (Talzenna)

  • EMA status: Authorised
  • Indication (prostate cancer):
    • In combination with enzalutamide for mCRPC

❌ Rucaparib

  • EMA-authorised (ovarian cancer)
  • Not authorised for prostate cancer in the EU

❌ Niraparib (monotherapy)

  • EMA-authorised (ovarian cancer)
  • For prostate cancer, available as:
    • Akeega (niraparib + abiraterone) — EMA authorised for prostate cancer

3️⃣ What does PROfound show?

PROfound (NCT02987543)

Design:

  • Phase 3
  • mCRPC with HRR mutations
  • Prior progression on enzalutamide or abiraterone
  • Olaparib vs physician’s choice (enzalutamide or abiraterone)

Primary endpoint:

  • Radiographic progression‑free survival (rPFS)

Key findings (Cohort A: BRCA1/2 or ATM mutations)

  • Significant improvement in rPFS with olaparib
  • Improved overall survival
  • Higher objective response rate
  • Benefit strongest in BRCA2 subgroup

Clinical significance:

  • Established PARP inhibition as standard of care in HRR‑mutated mCRPC
  • Led to regulatory approval (FDA and EMA)

4️⃣ What does TALAPRO‑2 show?

TALAPRO‑2 (NCT03395197)

Design:

  • Phase 3
  • Talazoparib + enzalutamide vs enzalutamide alone
  • First‑line mCRPC
  • Included both all‑comers and HRR‑mutated populations

Primary endpoint:

  • Radiographic progression‑free survival (rPFS)

Key findings:

  • Significant rPFS improvement with:

    Talazoparib + enzalutamide

  • Benefit most pronounced in HRR‑mutated tumors, including BRCA2
  • Higher rates of:
    • Anemia
    • Cytopenias

Clinical implication:

  • Supports PARP inhibitor + AR pathway inhibitor combination in first‑line mCRPC
  • Basis for regulatory approval of the combination

5️⃣ What does the FDA require as companion diagnostic?

✅ Olaparib (Lynparza)

FDA requires:

An FDA‑approved companion diagnostic test
to detect deleterious or suspected deleterious HRR gene mutations, including BRCA1/2

  • Tumor tissue or plasma (ctDNA)
  • Germline or somatic testing allowed
  • Companion diagnostic information available via FDA companion diagnostics database

✅ Talazoparib (Talzenna)

For mCRPC:

  • Requires detection of HRR gene mutations
  • Genes include:
    • BRCA1
    • BRCA2
    • ATM
    • PALB2
    • CHEK2
    • RAD51C
    • and others

⚠️ Label specifies:

No single specific FDA‑approved CDx is currently mandated, but HRR mutation testing is required for patient selection.

6️⃣ Practical summary for BRCA2‑mutant mCRPC

Question
Answer
Drug class
PARP inhibitors
EMA authorised?
✅ Olaparib; ✅ Talazoparib (combo)
Evidence
PROfound → post‑NHA setting; TALAPRO‑2 → 1L combo
Strongest mutation signal
BRCA2
FDA CDx requirement
HRR mutation testing required; FDA‑approved CDx for olaparib

🔎 Bottom Line

For BRCA2‑mutant mCRPC, PARP inhibition is now a standard targeted strategy:

  • After prior ARPI: Olaparib (PROfound)
  • First‑line combination: Talazoparib + enzalutamide (TALAPRO‑2)
  • Requires confirmed HRR mutation testing (tumor or germline)

If useful, I can also provide:

  • A comparison of PROfound vs PROpel vs MAGNITUDE vs TALAPRO‑2
  • A treatment algorithm for BRCA2‑mutant mCRPC
  • Toxicity management comparison between olaparib and talazoparib